Neumora Therapeutics, Inc.(NMRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NMRA Neumora Therapeutics, Inc.

休市中 06-26 16:00:00 EDT

1.64

+0.13

+8.61%

盘后1.64

+0.000.00%

19:12 EDT

最高1.66	最低1.48	成交量1,498万
今开1.50	昨收1.51	日振幅11.92%
总市值3.04亿	流通市值1.77亿	总股本1.85亿
成交额2,444万	换手率13.87%	流通股本1.08亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":1.64,"timestamp":1782504000000,"preClose":1.51,"halted":0,"volume":14976481,"hourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.64,"latestTime":"19:12 EDT","volume":2559364,"amount":4197126.22812,"timestamp":1782515537068,"change":0,"changeRate":0,"amplitude":0.015244},"delay":0,"changeRate":0.086092715231788,"floatShares":108000000,"shares":185284244,"eps":-1.327887,"marketStatus":"休市中","change":0.13,"latestTime":"06-26 16:00:00 EDT","open":1.5,"high":1.66,"low":1.48,"amount":24444432.570428,"amplitude":0.119205,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.327887,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":1.51,"preHourTrading":{"tag":"盘前","latestPrice":1.5797,"preClose":1.51,"latestTime":"08:43 EDT","volume":1227,"amount":1823.3428589999999,"timestamp":1782477796173,"change":0.0697,"changeRate":0.046159,"amplitude":0.095232},"postHourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.64,"latestTime":"19:12 EDT","volume":2559364,"amount":4197126.22812,"timestamp":1782515537068,"change":0,"changeRate":0,"amplitude":0.015244},"volumeRatio":8.39916823202477,"impliedVol":1.387,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/NMRA","defaultTab":"news","newsList":[{"id":"1119005478","title":"Neumora Therapeutics 公布 Koastal 三期项目数据并更新业务及研发管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1119005478","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119005478?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:01","pubTimestamp":1781524915,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics 公司宣布了其 Koastal 三期临床试验项目的数据结果，同时提供了最新的业务进展与研发管线更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177311422","title":"Neumora Therapeutics宣布因三期临床失败而终止Navacaprant研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1177311422","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177311422?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:01","pubTimestamp":1781524909,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics公司已决定终止其核心候选药物Navacaprant的后续开发工作。这一决定源于该药物在两项关键的三期临床试验——Koastal-2与Koastal-3中未能达到预设的主要疗效终点。两项试验的数据均显示，Navacaprant在治疗重度抑郁症方面，其疗效与安慰剂相比未显示出具有统计学意义的显著优势。此次研发挫折无疑对Neumora Therapeutics构成了重大打击。Navacaprant曾被公司寄予厚望，视为其产品管线中极具潜力的重磅资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103348728","title":"Neumora Therapeutics公司：现金及等价物达1.471亿美元，预计可维持运营至2027年第三季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1103348728","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103348728?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:17","pubTimestamp":1778152637,"startTime":"0","endTime":"0","summary":"生物制药公司Neumora Therapeutics, Inc. (NMRA) 宣布，其持有的现金及现金等价物总额达到1.471亿美元。公司预计，凭借当前充足的资金储备，其运营活动将获得有力支持，资金可维持公司正常运转至2027年第三季度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172115897","title":"Neumora Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1172115897","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172115897?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:55","pubTimestamp":1774868118,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc.（以下简称“Neumora”）近日正式披露了2025年第四季度及全年的财务报告，并同步更新了公司最新业务动态。此次公布的信息涵盖了公司在财务表现、研发进展及战略规划方面的关键内容，为投资者及市场关注者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604917764","title":"Neumora Therapeutics, Inc.盘中异动 临近收盘股价大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604917764","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604917764?lang=zh_cn&edition=full","pubTime":"2026-01-17 04:56","pubTimestamp":1768596970,"startTime":"0","endTime":"0","summary":"北京时间2026年01月17日04时56分，Neumora Therapeutics, Inc.股票出现波动，股价急速下跌5.16%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，成立的初衷是通过采用一种全新的方法来开发脑部疾病治疗方案，以应对脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011704561097a2270f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011704561097a2270f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NMRA","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189252236","title":"Neumora Therapeutics阿尔茨海默症早期研究结果积极 股价应声上涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189252236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189252236?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:32","pubTimestamp":1767623547,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics公司公布其早期阿尔茨海默病研究的积极结果后，市场反应热烈，该公司股价大幅攀升10%。\n这项突破性进展为治疗这种神经退行性疾病带来了新的希望，显著提振了投资者信心。研究数据展示了公司在神经科学领域的研发实力，预示着其候选药物具备良好的开发前景。\n股价的强劲表现反映了市场对Neumora Therapeutics创新管线的认可，也凸显了生物技术板块对重大临床进展的高度敏感性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151848712","title":"Neumora Therapeutics公布2026年管线战略与关键里程碑展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1151848712","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151848712?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:37","pubTimestamp":1767613067,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc.今日宣布其关键管线进展与2026年预期里程碑，这些成果将支撑公司通过新一代创新疗法重塑神经科学药物开发的使命，为脑疾病患者提升治疗结果与生活质量。Neumora宣布计划在每项KOASTAL研究中增加招募人数，在原始目标332例基础上最高提升25%。Neumora Therapeutics, Inc.是一家临床阶段生物制药公司，致力于通过革新脑疾病治疗开发模式应对全球脑疾病危机。除法律要求外，Neumora无义务更新或修订前瞻性陈述。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4132","BK4007","BK4563","PAM","NMRA","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131995877","title":"Neumora Therapeutics公布NMRA-511治疗阿尔茨海默病激越症状的1B期信号探索研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1131995877","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131995877?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:32","pubTimestamp":1767612720,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics公司近日宣布，其针对阿尔茨海默病激越症状研发的药物NMRA-511，在1B期信号探索研究中取得了积极成果。这项研究旨在评估NMRA-511的安全性、耐受性及初步疗效信号，结果显示该药物在主要终点和关键次要终点上均表现出显著改善。数据表明NMRA-511有望为阿尔茨海默病相关的激越症状提供新的治疗选择，公司计划基于这些结果推进后续临床开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518276710","title":"Neumora Therapeutics, Inc.盘中异动 早盘股价大跌5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276710","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518276710?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:55","pubTimestamp":1741618521,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时55分，Neumora Therapeutics, Inc.股票出现异动，股价大幅下跌5.37%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022552198a2b17c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022552198a2b17c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518210334","title":"Neumora Therapeutics, Inc.2024财年实现净利润-2.44亿美元，同比减少3.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518210334","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518210334?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449669,"startTime":"0","endTime":"0","summary":"3月9日，Neumora Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.44亿美元，同比减少3.39%；其中营业收入为0.00美元，每股基本收益为-1.53美元。从资产负债表来看，Neumora Therapeutics, Inc.总负债29.91百万美元，其中短期债务1.85百万美元，资产负债比为0.11，流动比率为0.11。机构评级：截至2025年3月9日，当前有6家机构对Neumora Therapeutics, Inc.目标价做出预测，其中目标均价为6.67美元，其中最低目标价为2.00美元，最高目标价为18.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000231a266b3dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000231a266b3dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NMRA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517727458","title":"Stifel：下调Neumora Therapeutics(NMRA.US)评级，由买入调整至持有评级, 目标价由6.00美元调整至2.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517727458","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517727458?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:44","pubTimestamp":1741365844,"startTime":"0","endTime":"0","summary":"Stifel：下调Neumora Therapeutics(NMRA.US)评级，由买入调整至持有评级, 目标价由6.00美元调整至2.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08004448604766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NMRA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516162054","title":"HC Wainwright & Co.：维持Neumora Therapeutics(NMRA.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516162054","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516162054?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:55","pubTimestamp":1741089323,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Neumora Therapeutics(NMRA.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至18.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04195548519788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NMRA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177838069","title":"Neumora Therapeutics 2024年第四季度GAAP每股收益$(0.37)，优于预期的$(0.45)，现金余额为3.076亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177838069","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177838069?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:18","pubTimestamp":1741004329,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics(LENZ) 2024年第四季度GAAP每股收益$(0.37)，优于预期的$(0.45)，现金余额为3.076亿美元以上内容来自Benzinga Earnings专栏，原文如下：Neumora $Therapeutics(LENZ)$ Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512859654","title":"Neumora Therapeutics, Inc.盘中异动 早盘股价大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512859654","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512859654?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:56","pubTimestamp":1739976980,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时56分，Neumora Therapeutics, Inc.股票出现异动，股价大幅下跌5.20%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225620a24bffeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225620a24bffeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","NMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511213325","title":"Neumora Therapeutics, Inc.盘中异动 早盘快速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511213325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511213325?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:23","pubTimestamp":1739460231,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时23分，Neumora Therapeutics, Inc.股票出现波动，股价快速跳水5.00%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232351a244b6ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232351a244b6ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509493522","title":"Neumora Therapeutics, Inc.盘中异动 下午盘快速上涨5.11%报1.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509493522","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509493522?lang=zh_cn&edition=full","pubTime":"2025-02-05 03:05","pubTimestamp":1738695957,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日03时05分，Neumora Therapeutics, Inc.股票出现异动，股价急速拉升5.11%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.38%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205030557961801c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205030557961801c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NMRA","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508144364","title":"Neumora Therapeutics, Inc.盘中异动 股价大跌5.15%报1.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508144364?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:03","pubTimestamp":1738594983,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时03分，Neumora Therapeutics, Inc.股票出现波动，股价急速下跌5.15%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230303abc10e72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203230303abc10e72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505179270","title":"Neumora Therapeutics, Inc.盘中异动 股价大跌5.29%报1.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505179270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505179270?lang=zh_cn&edition=full","pubTime":"2025-01-23 23:27","pubTimestamp":1737646057,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日23时27分，Neumora Therapeutics, Inc.股票出现波动，股价大幅跳水5.29%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123232738960e5015&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123232738960e5015&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","NMRA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501773593","title":"Neumora Therapeutics, Inc.盘中异动 早盘股价大跌6.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501773593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501773593?lang=zh_cn&edition=full","pubTime":"2025-01-08 22:30","pubTimestamp":1736346655,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日22时30分，Neumora Therapeutics, Inc.股票出现异动，股价快速下挫6.59%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108223055a21a523f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108223055a21a523f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NMRA","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501008362","title":"Neumora Therapeutics, Inc.盘中异动 早盘大幅上涨7.66%报2.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501008362","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501008362?lang=zh_cn&edition=full","pubTime":"2025-01-07 22:32","pubTimestamp":1736260355,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日22时32分，Neumora Therapeutics, Inc.股票出现波动，股价快速拉升7.66%。Neumora Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Neumora Therapeutics, Inc.公司简介：Neumora Therapeutics Inc 是一家临床阶段的生物制药公司，其成立的目的是通过采取一种完全不同的方法来开发脑部疾病的治疗方法，以应对全球脑部疾病危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223235a218e75c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223235a218e75c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neumoratx.com","stockEarnings":[{"period":"1week","weight":0.0861},{"period":"1month","weight":-0.1183},{"period":"3month","weight":-0.2961},{"period":"6month","weight":-0.0787},{"period":"1year","weight":1.0515},{"period":"ytd","weight":-0.0838}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neumora Therapeutics, Inc.最初于2019年11月在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，旨在通过提出下一代脑渗透化学新疗法，为患者提供更好的治疗结果和生活质量，以应对其这一代人面临的最大医疗挑战。该公司的治疗管道目前包括针对各种服务不足的流行疾病的新作用机制的项目。","exchange":"NASDAQ","name":"Neumora Therapeutics, Inc.","nameEN":"Neumora Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neumora Therapeutics, Inc.(NMRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Neumora Therapeutics, Inc.(NMRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Neumora Therapeutics, Inc.,NMRA,Neumora Therapeutics, Inc.股票,Neumora Therapeutics, Inc.股票老虎,Neumora Therapeutics, Inc.股票老虎国际,Neumora Therapeutics, Inc.行情,Neumora Therapeutics, Inc.股票行情,Neumora Therapeutics, Inc.股价,Neumora Therapeutics, Inc.股市,Neumora Therapeutics, Inc.股票价格,Neumora Therapeutics, Inc.股票交易,Neumora Therapeutics, Inc.股票购买,Neumora Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neumora Therapeutics, Inc.(NMRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Neumora Therapeutics, Inc.(NMRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}